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There is a growing interest on the role of autophagy in diabetes pathophysiology, where
development of neuropathy is one of the most frequent comorbidities. We have previously
demonstrated that neuropathic pain after nerve damage is exacerbated in autophagy-defec-
tive heterozygous Ambra1 mice. Here, we show the existence of a prediabetic state in
Ambra1 mice, characterized by hyperglycemia, intolerance to glucose and insulin resis-
tance. Thus, we further investigate the hypothesis that prediabetes may account for the
exacerbation of allodynia and chronic pain and that counteracting the autophagy deficit may
relieve the neuropathic condition. We took advantage from caloric restriction (CR) able to
exert a double action: a powerful increase of autophagy and a control on the metabolic
status. We found that CR ameliorates neuropathy throughout anti-inflammatory and meta-
bolic mechanisms both in Ambra1 and in WT animals subjected to nerve injury. Moreover,
we discovered that nerve lesion represents, per se, a metabolic stressor and CR reinstates
glucose homeostasis, insulin resistance, incomplete fatty acid oxidation and energy metab-
olism. As autophagy inducer, CR promotes and anticipates Schwann cell autophagy via
AMP-activated protein kinase (AMPK) that facilitates remyelination in peripheral nerve. In
summary, we provide new evidence for the role of autophagy in glucose metabolism and
identify in energy depletion by dietary restriction a therapeutic approach in the fight against
neuropathic pain.
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Introduction
Prediabetes reflects a metabolic alteration due to causes not completely known even if family
history and genetics appear to play an important role. It is defined as a state of abnormal glu-
cose homeostasis in which deficiency or resistance to insulin are distinctive features [1]. Predi-
abetes can prelude to type 2 diabetes or metabolic syndrome and it can be associated to
different comorbidities such as neuropathy [2].
Derangement of glucose metabolism and hyperglycemia are regarded as key factors in the
diabetes pathogenesis and comorbid neuropathy [3]. Interestingly, there is mounting evidence
that autophagy, as key cell-protective mechanism, also plays a fundamental role in insulin
secretion and β cells viability [4]. Basically, autophagy is a catabolic process of self-degradation
for the preservation of cellular and mitochondrial homeostasis [5]. Autophagy is involved in
the prevention of β cells death via its activity against protein aggregates that accumulates in β
cells as consequence of hyperglycemia-induced oxidative stress [6–9]. Because of its funda-
mental role in degrading misfolded proteins, autophagy counteracts not only oxidative but
also endoplasmic reticulum (ER) stress, which are both key elements in β cells toxicity and dia-
betes pathogenesis. Indeed, defective autophagy may increase ER stress that, in turn, is
involved in insulin resistance [10]. Of note, hypoglycemic drugs for type 2 diabetes are β cells
protective and autophagy inducers [11].
We recently demonstrated that pharmacological inhibition of autophagic activity, or defec-
tive autophagy in transgenic mice for the activating molecule in Beclin-1-regulated autophagy
(Ambra1(+/gt), Ambra1 hereafter) [12], exacerbated allodynia response and persistence of
neuropathic pain (NeP) [13]. Schwann cells (SCs) are essential for reparative process after
peripheral nerve injury to control Wallerian degeneration (WD), which involves the progres-
sive demyelination of peripheral nerves [14, 15]. Moreover, SCs are responsible for axons mye-
lin ensheathment and paracrine trophic support to nerve [16]. When WD begins, SCs degrade
and remove degenerated axons and myelin [14] throughout a process known as myelinophagy
[4] (i.e. SCs autophagy) which contributes to prevent NeP chronification and facilitate nerve
regeneration [13]. Nevertheless, the involvement of SCs in diabetic neuropathy and the role
played by changes in energy metabolism and impairment of autophagy machinery is still
mostly unknown. Interestingly, hyperglycemia has been observed to derange SCs function,
induce apoptotic death [17] and de-myelination and de-differentiation of SCs into immature
cells [18].
In view of accumulated evidence supporting the pathogenetic role played by autophagy in
diabetes, we wondered whether autophagy-defective Ambra1 mice may show altered energy
metabolism and diabetic-like signs, and whether a non-pharmacological enhancement of
autophagy may revert or attenuate the exacerbation of NeP following nerve damage. For this
purpose, the dual properties of caloric restriction (CR), as powerful autophagy mimetic and
metabolic regulator, are here exploited. Energy depletion in the form of calorie intake restric-
tion is a well characterized strategy to enhance autophagy, and promote health and longevity
[19]. Hence, in the present study, we investigated the pathophysiology emerging from autop-
hagy deficiency linked to metabolic dysregulation and peripheral neuropathy.
Materials and methods
Animals
Upon their arrival in the laboratory (at least 2 weeks before the experiments), animals were
housed in standard transparent plastic cages, in groups of 4 per cage, lined with sawdust under
a standard 12/12- hour light/dark cycle (7:00 am/7:00 pm), with food and water available ad
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libitum. Care and handling of the animals were in accordance with the guidelines of the Com-
mittee for Research and Ethical Issues of IASP (PAIN 1983, 16, 109–110) and with the Euro-
pean and Italian National law (DLGs n.26 del 04/03/2014, application of the European
Communities Council Directive 2010/63/UE–Authorization n˚ DM 32/2014, Italian Ministry
of Health) on the use of animal for research.
Wild-type (WT) CD1 male mice (Charles River Laboratories, Como, Italy) and heterozy-
gous Ambra1 transgenic (CD1 background Ambra1+/gene trap–Ambra1+/gt) male mice 3
months old were used (obtained from Prof. F. Cecconi) [12]. Female mice were initially used
to evaluate potential gender effects in the neuropathic phenotype of Ambra1 mice (S1 Fig).
Not revealing significant differences in Ambra1 mice, all the experiments were performed in
male mice.
All efforts were made to minimize animal suffering and to use only the number of animals
necessary to produce reliable scientific data.
All the experiments were performed blind as for treatment group.
Surgery
The procedure of monolateral chronic constriction injury (CCI) of sciatic nerve [20] induces
mechanical allodynia and is a model of NeP.
It was performed under anesthesia (0.02 g/kg ketamine+ 5mg/Kg xylazine–Ketavet; Sigma-
Aldrich USA; intraperitoneally -IP) as described elsewhere [21]. Briefly, the middle third of
the sciatic nerve was exposed through a longitudinal skin incision, 3 ligatures were made with
non-absorbable gut (5–0 chromic gut, Ethicon, Italy), tied around the sciatic nerve and the
wound was then closed with 4–0 silk suture (Ethicon, Italy). Afterward, injured and uninjured
hindpaw will be referred as ipsilateral and contralateral, respectively. Mice develop mechanical
allodynia usually within 2–3 days. At the end of the experiments, mice were sacrificed, and the
presence of the ligature was checked.
Dietary restriction
In S1 Table are summarized all experimental groups, conditions, time-points and number of
animals utilized.
Mice with body weight (BW) between 40 and 45 g were randomly attributed either to Stan-
dard diet (ST—ad libitum fed mice; n = 10/12 for each genotype) or to Caloric Restriction
group (CR; n = 10/12 for each genotype) from the day of CCI (D0) up day 7 (D7) post-CCI.
To define the individual amount of feed ration, mice were isolated 15 days before the CCI
and BW and food intake were recorded at approximately the same time (11:00 AM– 1:00 PM)
for all mice. Food intake was determined daily by subtracting the weight of the food pellets
remaining in the food hopper after the initial amount given (approximately 80 g).
During dietary restriction, mice in CR received weighed food pellets corresponding to the
40% less of their daily consumption in ad libitum condition. Pellets were dropped directly into
each cage for easy access. Water was provided ad libitum.
Mechanical allodynia
CCI-induced mechanical allodynia was tested by using a Dynamic Plantar Aesthesiometer
(Model 37,400, Ugo Basile, Comerio, Italy) described elsewhere [21]. For habituation, mice
were placed 30’ before test in the experimental room and in plastic cages with a wire net floor
5 min before the experiment. Starting from day 3 after CCI, withdrawal threshold was mea-
sured about one time at week (days 3, 7, 10, 14, 21, 28, 40, 45). The end point was defined by
the total recovery from at least one experimental group. Each testing day, the withdrawal
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thresholds of ipsilateral and contralateral hindpaws were taken as the mean of 3 consecutive
measurements per paw.
Glycemia and triglycerides
Blood glucose and triglycerides (TGs) were measured using a Multicare Test Strips apparatus
(Biochemical Systems International, Italy) by tail clipping. For glycemia, naïve animals were
measured after overnight fasting while in baseline condition (BL, pre-CCI) and seven days
after CCI (post-CCI) in normal feeding condition, both in ST and CR dietary regimen. For
TGs, all experimental groups were measured in normal feeding condition. The same device
was used to measure glycemia level in Glucose Tolerance Test (GTT) and Insulin Tolerance
Test (ITT), here described.
Insulin and glucagon serum levels
Insulin and glucagon were measured in the serum of control or CCI non-fasted mice using
ELISA kits (RayBio Mouse Insulin Enzyme-linked immunosorbent assay (ELISA) Kit; RayBio-
tech Inc., Norcross, GA, USA and Quantikine ELISA Glucagon Immunoassay; USA & Canada
R&D Systems, Inc) according to the manufacturer’s recommendations. Serum samples were
harvested 24h, 3 days and 7 days after CCI. Specific antibody was coated onto the wells of the
microtiter plates. The intensity of the signal was proportional to the concentration of insulin
and glucagon present in the blood specimen and was read at 450 nm.
Glucose tolerance test and insulin tolerance test
GTT was performed in naïve animals in WT (n = 10) and in A+/- (n = 11) mice. Plasma glu-
cose at 0, 30’, 60’ e 120 min after intraperitoneal glucose administration (2g/kg) following over-
night fasting (16h), was registered. For ITT (WT n = 8; A+/- n = 7), plasma glucose was
recorded at 0, 30’, 60’ and 120 min after intraperitoneal insulin administration (1.5 U/Kg) fol-
lowing 5h fasting. Area under the curve (AUC) was calculated using trapezoidal rule.
Inflammatory mediators
Levels of various cytokines/chemokines in the sera and sciatic nerves tissue lysates were analyzed
using a mouse antibody array glass chip (RayBio Mouse Cytokine Antibody Array G series; Ray-
Biotech Inc., Norcross, GA, USA) in WT mice in all experimental conditions. To obtain serum
sample, blood was collected via beheading immediately following euthanasia, allowed to clot at
room temperature for 30 min and then centrifuged at 3000 rpm for 15 min. Lysis buffer (Raybio-
tech, Inc) containing proteinase inhibitor (Sigma Aldrich) was added to sciatic nerve homoge-
nates and 50 μg of each sample was added to the array. Incubation and washes were performed
following the manufacturer’s instructions described in supplemental material. Fluorescence
detection was performed using an Agilent G2564B microarray scanner (Agilent Technologies
Italy) and analysis was performed using the array testing services from RayBiotech.
Energy metabolism
Energy expenditure (EE), oxygen consumption (VO2) and respiratory quotient (RQ) were
measured by an indirect calorimeter (IC) system (TSE PhenoMaster/LabMaster System, Ger-
many) with a constant air flow of 0.35 L/min. Mice (N = 9–11 for each group) were adapted
for 6 hour to the metabolic chamber, and VO2 was measured every 20 minutes in individual
mice, starting at 7:00 PM and ending automatically after 48h (12h dark-light phase compari-
son). Room temperature was kept constant (22˚±1˚C). Formulae for parameters calculation
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are the following: RER = volume of CO2 produced/volume of O2 consumed, and is an index
of substrate use. MR was calculated as EE = (3.815 + 1.232 x VCO2/VO2) x VO2, as provided
by the TSE System. The MR and RER for each of the sample points were evaluated across the
48h of recording. Both MR and RER were also analyzed by considering animals’ resting condi-
tions (values included between 0 and 3 activity counts). Locomotor activity was assessed dur-
ing the IC by the number of infrared beams broken. Other details as described in a previous
study [22, 23].
Immunohistochemistry
Mice were sacrificed for immunofluorescence (IF) analysis of sciatic nerve (n = 3–5 for each
group) before and after CCI. Sciatic nerves collection, samples preparation and double staining
procedure are reported in [13]. Sections were first incubated overnight with primary antibod-
ies and then with secondary antibodies for 2 hours at room temperature. For autophagy evalu-
ation were used: anti-GFAP (mouse monoclonal, 1:100, Sigma-Aldrich or rabbit polyclonal,
1:100, Genemed) with anti-LC3 (mouse monoclonal, 1:100, nanotools) or anti P-mTOR (rab-
bit polyclonal, 1:100, CellSignaling) or P-AMPK (rabbit monoclonal, 1:100, CellSignaling).
For regenerative and proliferative processes were used: anti-GFAP (mouse monoclonal,
1:100, Sigma-Aldrich or rabbit polyclonal, 1:100, Genemed) with anti-GAP43 (mouse mono-
clonal, 1:100, Sigma Aldrich) or anti-Cdc2 (rabbit polyclonal, 1:100, Calbiochem), or anti-
NF200 (rabbit polyclonal, 1:100, Sigma-Aldrich).
For myelin sheath analysis were used: anti-GFAP (as below) with anti-MPZ (chicken poly-
clonal, 1:100, Millipore) or anti-PMP22 (rabbit polyclonal, 1:100, Sigma-Aldrich).
Sections were incubated with secondary antibodies, a mix of goat anti-mouse fluorescein-
conjugated (FITC, 1:100, Jackson Immuno Research) or goat anti-rabbit FITC (1:100, Santa
Cruz Biotechnology) and goat anti-rabbit rhodamine-conjugated (TRITC, 1:100, Jackson
Immuno Research) or donkey anti-chicken DyLight 549 (DYL, 1:100, Jackson Immuno
Research) for 2 hours at room temperature.
Finally, the sections were washed in PBS and then stained with Hoechst-33258 (DAPI,
1:500, Sigma-Aldrich, USA).
Confocal microscopy
Images of the immunostained sections were obtained by laser scanning confocal microscopy
using a TCS SP5 microscope (Leica Microsystem, Germany). All analyses were performed in
sequential scanning mode to rule out cross-bleeding between channels. High magnification
(63X) images of sciatic nerve sections were operated by I.A.S. software (Delta Systems, Italy).
Quantification was performed by using the ImageJ software (version 1.41, National Institutes
of Health, USA).
Fluorescence of different proteins observed was quantified (at least 2 slices x n = 3 each
group) by converting pixels in brightness values using the RGB (red, green and blue) as
described in [24].
Light microscopy
Sciatic nerves of perfused mice (2% paraformaldehyde and 2% glutaraldehyde in 0.1 M sodium
cacodylate buffer (Sigma-Aldrich, USA) pH 7.3) were removed and post-fixed in 2% OsO4
(Sigma-Aldrich, USA), stained in 2% aqueous uranyl acetate and washed. Dehydrated samples
were embedded in Epon-Araldite resin (Sigma-Aldrich, USA). Semi-thin (0.5 μm) sections,
toluidine blue stained, were examined by light microscopy (LM) (Image Pro-Plus 6.0 software-
magnification of 1500x).
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Protein isolation and immunoblotting
Sciatic nerves were homogenized in lysis buffer as described elsewhere [13] and mixed (n = 3
replicates for each WB), incubated on ice for 30 min and centrifuged at 13,000 g for 20 min.
The total protein content of resulting supernatant was determined. Proteins were applied to
SDS-PAGE and electroblotted on a PVDF membrane. Samples were incubated with the fol-
lowing primary antibodies: rabbit polyclonal anti-LC3, anti-AMPK, anti-pAMPK (T172),
anti-pmTOR (S2448), anti-mTOR (Cell Signaling); rabbit polyclonal anti ß- actin (Sigma);
mouse monoclonal anti-p62 (Santa Cruz); rabbit polyclonal anti-PMP22 (Millipore), rabbit
polyclonal anti-MPZ (Abcam), rabbit polyclonal anti-pATG13 (Rockland), rabbit polyclonal
Hsp90 (Santa Cruz).
All procedures for detection of Schwann cells autophagy in sciatic nerve follow the guide-
lines for autophagy monitoring [25].
Metabolomics: Direct infusion mass spectrometry
Whole blood from each mouse was collected on filter paper card as dried blood spot (DBS).
The determination of amino acids (AAs) and acylcarnitines (ACCs) was performed in DBS
samples by DIMS analysis, as already reported [26–29]. Whole blood from each mouse was
collected on filter paper card as dried blood spot (DBS), particularly suitable for small volume
samples. The determination of amino acids (AAs) and acylcarnitines (ACCs) was performed
in DBS samples by the addiction of isotopically labelled internal standards for each analyte of
interest prior to the extraction, according to the principle of isotope dilution internal standard-
ization. Filter paper disks were punched out from DBS samples and quality controls (QCs)
using an automatic puncher, into a polypropylene microtitre plate. The diameter of the disk is
approximately 3.2 mm (3–3.2 μL whole blood). 100 μL of the extraction solution containing
internal standards were added to each well containing a filter paper disk. The internal stan-
dards as well as the extraction solution and the QCs were obtained from the NeoBase Non-
derivatized MSMS Kit (Perkin Elmer Life and Analytical Sciences, Turku, Finland). Once cov-
ered, the plate was shaken in a thermo mixer (700 rpm, 45˚C, 50 minutes). 75 μL from the con-
tents of each well were transferred to a new microplate. The plate was placed in the
autosampler for analysis. The QCs from the same kit were run in the same way of the real sam-
ples. The low and high blood spot QCs from the kit were run in replicate in each plate, before
and after the real samples. The direct infusion mass spectrometry (DIMS) analysis for the eval-
uation of metabolite profile in DBS samples was performed using a Liquid Chromatography
Tandem Quadrupole Mass Spectrometry LC/MS/MS system (Alliance HT 2795 HPLC Separa-
tion Module coupled to a Quattro Ultima Pt ESI, Waters Corp., Manchester, UK). The instru-
ment operated in positive electrospray ionization, with multiple reaction monitoring (MRM)
as acquisition mode, using MassLynx V4.0 Software (Waters Corp.) with auto data processing
by NeoLynx (Waters Corp.). Autosampler injections of 30 μL were made into the ion source
directly by a narrow peek tube. The total run time was 1.8 minute, injection-to-injection. The
mass spectrometer ionization source settings were optimized for maximum ion yields for each
analyte. Capillary voltage was 3.25 kV, source temperature was 120˚C, desolvation temperature
was 350˚C and the collision cell gas pressure was 3–3.5 e-3mbar Argon.
The list of analyzed metabolites and a description of abbreviations as used in text are avail-
able in S3 Table.
Experimental design and statistical analysis
Details regarding all experimental groups, conditions, time-points and number of animals are
condensed in S1 Table.
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Data were expressed as mean ± standard error of the mean. Complete results of the statisti-
cal analyses and exact p-values are reported in the results section and in S2 and S4 Table for
metabolomics. Depending on data, statistical analysis was performed either by unpaired t test,
1-way analysis of variance (ANOVA) or 2-way ANOVA for repeated measures while for small
samples (N<5 animals) and groups>3, non-parametric analysis was performed by Kruskall-
Wallis.
Tukey–Kramer test has been used for post-hoc analysis in multiple comparison or t-Test
for single comparison.
Variable Importance in Projection (VIP) scores was calculated by estimating the impor-
tance of each variable used in the PLS-DA model [30]. Baseline differences between WT and
Ambra1 mice, the effects of CCI on whole blood AAs, ACCs, and sums of short-chain, odd-
chain, 3-Hydroxy/diCarboxy, medium and long-chain, and long-chain ACCs in the same
mouse strains were assessed by two-factor mixed design ANOVA followed by Fisher post-hoc
test, using the general linear model (GLM) approach. Genotype and CCI were the independent
factors.
The effect of CR on AAs, ACCs, and sums of 3-Hydroxy/diCarboxy, medium, and long-
chain ACCs in post-CCI WT and post-CCI Ambra1 mice were assessed by two-factor
ANOVA followed by Fisher post-hoc test with genotype and diet regimen as independent
factors.
When the assumption of the homogeneity of the variance was rejected by Levene test, the
aligned rank transformation (ART) of data was performed.
Unsupervised hierarchical cluster analysis, supervised Partial Least Square Discriminant
Analysis (PLSDA), and Receiver Operating Characteristic (ROC) analysis were performed
using MetaboAnalyst statistical analysis module [30] using the default settings.
The quality of the PLS-DA model was expressed by R2 and Q2 parameters, representing the
explained variance and the predictive capability of the model, respectively.
A variable with a VIP score higher than one is considered important in a given model.
Mean centering, unit variance scaling, and log transformation of metabolite concentrations
were performed before multivariate data analysis.
Results
Ambra1 autophagy-defective mice show metabolic dyshomeostasis and
prediabetes hallmarks
The analysis of metabolic phenotype discloses the existence of a prediabetic condition in
Ambra1 mice. Body weight (BW) did not differ between the two genotypes (slightly increased
in Ambra1 mice), but Ambra1 mice resulted hyperglycemic after overnight fasting (t19 =
2,272, p .034) and hyperinsulinemic (t4 = -31,05, p< .0001) and hyperglucagonemic (t4 =
-9,834, p .0006), in non-fasting conditions (Fig 1A). Triglycerides plasma levels were lower in
non-fasted Ambra1mice (t30 = -2,217, p .034; Fig 1A) that also showed significantly higher gly-
cemia levels after 16h fasting (time 0’) and an increase of glycemic levels after glucose loading
(GTT and AUC; main effect—time F3,19 = 16,43 p< .0001; t19 = 2,272, p .034; Fig 1B). In ITT
a pattern of insulin resistance with significant higher blood glucose levels was found in 5 hours
fasted mice (main treatment effect F1,15 = 6,61 p .021; main effect–time F3,15 = 22,02 p< .0001;
60’: t15 = 2,15 p .048; 120’: t15 = 2,57 p .021; Fig 1B).
To further understand whole-body energy metabolism, we used the indirect calorimetry
(IC) analysis to investigate energy expenditure (EE), resting EE (REE) and nutrient substrate
oxidation (respiratory exchange ratio, RER) in autophagy-defective mice. Fig 1C shows that in
BL condition no differences are observable in EE between WT and Ambra1 mice; by contrast,
Caloric restriction as autophagy inducer to counteract neuropathy and pain
PLOS ONE | https://doi.org/10.1371/journal.pone.0208596 December 10, 2018 7 / 26
Fig 1. Metabolic phenotype of wild type and Ambra1 mice in baseline condition. (A) Body weight, Glycemia measured after overnight fasting,
glucagon, insulin and triglycerides plasma levels in BL condition, showing significant differences between the two genotypes. (B) Glucose Tolerance
Test: plasma glucose at 0 and 30’, 60’ and 120 min after intraperitoneal glucose administration (2g/kg, arrow) following overnight fasting. AUC shows
significant increase (around 12%) in Ambra1 mice. ANOVA for repeated measures revealed significant effects for Time (p<0.0001) and for Time x
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higher REE was showed by Ambra1 mice (t36 = 9.28, p< .0001). Moreover, the increase of
RER demonstrates that substrate oxidation, (i.e. fat oxidation), is reduced in Ambra1 mice
(t36 = 14.01, p< .0001; Fig 1C).
Next, we investigated blood alterations in AAs and ACCs, as indirect markers of fatty acid
and protein catabolism, to identify a panel of biomarkers as potential metabolic signature [31]
of Ambra1 mice (Fig 1D). In BL, Ambra1 mice showed higher levels of long-chain 3-hydroxy
ACCs (C16OH, C18:1OH, C18OH), AAs ornithine (Orn) and asparagine (Asn), and lower
levels of C3 (propionylcarnitine) (see also S1 Table,S2 Fig for details and statistics). Supervised
PLSDA showed that AAs and ACCs metabolic signatures discriminate between WT and
Ambra1 mice (R2 = 0.91, Q2 = 0.75; S2 Fig) indicating that C3, C16OH, C18:1OH, C18OH,
and Orn are the most important variables contributing to the separation between WT and
Ambra1 mice in BL condition. Unsupervised hierarchical cluster analysis further highlights
the importance of these five metabolites for genotype discrimination, providing a sensitivity of
100% and a specificity of 83.3%.
Caloric restriction relieves neuropathic pain, nerve damage and
Ambra1-associated metabolic alterations
Mechanical allodynia was measured before mice underwent CCI (pre-CCI), and no differences
were revealed between genotypes (Fig 2A). Mice that underwent CCI of sciatic nerve develop
neuropathic pain in the hindpaw ipsilateral (IPSI) to the lesion, as showed in WT mice in ST
condition (WT ST CONTRA vs WT ST IPSI Fig 2A). No significant differences were observed
between allodynia level in contralateral hindpaw and measurement in basal condition (pre-
CCI). Hence, contralateral hindpaw withdrawal threshold was considered as control level. We
previously demonstrated [13] that Ambra1 mice subjected to CCI never recovered from neu-
ropathy, as here confirmed (Fig 2A). When subjected to CR, both WT and Ambra1 mice
reduced allodynia response (main treatment effect F7,82 = 264,04 p< .0001; interaction treat-
ment�time F49,574 = 3,517 p< .0001 Fig 2A). WT totally recovered from neuropathy thus
approximating the mechanical threshold showed by the contralateral hindpaw (Fig 2A, D45
WT CR CONTRA vs WT CR IPSI t22 = 1,6 p .123). Ambra1 mice showed a parallel but not
identical reduction of allodynia significantly decreasing pain (A+/- CR vs A+/- ST; D7-D21/
D45 p< .0001 Tukey HSD; D28-D40 p< .05 Tukey HSD).
By studying the metabolic changes induced by CR regimen, we unexpectedly discovered
that CCI had per se a metabolic impact. Nerve injury produced different effects on the two
genotypes depending on the exposure to CR. Indeed, robust changes of glycemia, triglycerides,
insulin and glucagon were found during neuropathic pain development and CR regimen (Fig
2C–2F). As expected BW was lower in mice subjected to CR while CCI did not affect BW (Fig
2B).
In non-fasted animals glycemia (main treatment effect F1,1 = 8,37 p .009; main effect–time
F2,20 = 6,31 p .004; treatment
�time F2,2 = 6,3 p .004) was altered by the neuropathy induction,
Genotype interaction (p<0.05). Insulin Tolerance Test: plasma glucose at 0 and 30’, 60’ and 120 min after intraperitoneal insulin administration (1.5
U/Kg, arrow) following 5 hours fasting. AUC shows a significant increase (+32%) in Ambra1 mice. ANOVA for repeated measures revealed
significant effects for Genotype (p<0.05) and Time (p<0.0001). (C) Energy metabolism measured by continuous 48-h recording of energy
expenditure (EE), total resting EE (REE) and respiratory exchange ratio (RER), assessed via the indirect calorimetry. Heat is expressed as Kcal emitted
per hour (h)/Kg. (D) Whole blood amino acid (AA) and acylcarnitine (ACC) profiling of wild type (WT BL) and Ambra1 (A+/- BL). Variable
importance on projection (VIP) plot: VIP scores>1 indicate a high relevance for the selected AAs and ACCs in the predictive model. Heatmap
visualization of unsupervised hierarchical clustering analysis based on whole blood concentrations of C3, C16OH, C18:1OH, C18OH, and Orn in the
study groups. Each bar represents a metabolite coded in accordance with its concentration expressed with a normalized scale ranging from light grey
(low level) to dark grey (high level). Rows depict analysed AAs and ACCs, columns indicate samples � p<0.05 and �� p<0.001 vs WT.
https://doi.org/10.1371/journal.pone.0208596.g001
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decreasing 24h after CCI in WT ST mice (WT ST vs WT BL; p< .05 Tukey HSD) and at 7
days in Ambra1 ST mice (A+/- ST vs A+/- BL, p< .05 Tukey HSD) as compared to the BL
condition. CR was able to change glycemia, and in WT mice a lower glycemia was observable
at D3 and D7 (WT CR vs WT ST, p< .05 Tukey HSD; Fig 2C) and at D3 in Ambra1 mice (A
+/- CR vs A+/- ST, p< .05 Tukey HSD; Fig 2C).
Also triglycerides levels were affected by nerve lesion both in WT (24h and D7; WT ST vs
WT BL p< .0001 Tukey HSD, Fig 2D) and in Ambra1 mice (24h and D3; A+/- ST vs A+/- BL,
p< .0001 Tukey HSD), while CR decreased triglycerides in both genotypes at all time points
(WT CR vs WT ST and A+/- CR vs A+/- ST; p< .0001 Tukey HSD) except than at D7 in
Ambra1 mice (main treatment effect F1,1 = 223,1 p< .0001; interaction main treatment
effect�genotype F1,20 = ; 6,93 p< .015; main effect–time F2,20 = 15,16 p< .0001; interaction
genotype�time F2,2 = 12,62 p< .000; interaction main treatment effect
�time F2,2 = 8,02
p .0012; interaction main treatment effect�time�genotype F2,40 = 8,74 p .0007, Fig 2D).
Moreover, CCI induced changes in glucagon levels, and hyperglucagonemia was observed
in WT ST (D3) and Ambra1 ST mice (24h) (H14 = 43,262 p< .0001; WT ST vs WT BL t4 =
26,946 p< .0001; A+/- ST vs A+/- BL t4 = 8,365 p .0011; Fig 2E). CR counteracted hypergluca-
gonemia at 24h in Ambra1 mice and D3 in WT, reporting the level to basal value but induced
a strong increase at D3 in Ambra1 mice (A+/- CR vs A+/- ST; t4 = -9,248 p .0008).
As for the other metabolic parameters, CCI produced also changes in insulin levels which
were highly susceptible to CR (H9 = 25,09 p .0029; Fig 2F). A decrease was observed in WT ST
mice at 24h (WT ST vs WT BL; t4 = -3,27 p .03), D3 (t4 = -8,38 p .0011) and D7 (t4 = -5,22 p
.0064); as well as in Ambra1 mice (A+/- ST vs A+/- BL t4 = -27,26 (24h), -28,54 (D3), -30,78
(D7) p< .0001; Fig 2F), which were completely downregulated by CR at 24h and D3 in both
genotypes. Conversely, at D7 we found a partial recover of insulin levels in Ambra1 CR mice,
which showed values comparable to those observed before CCI in normoglycemic WT mice
(Fig 2F).
The impact of CCI and CR on energy metabolism was reassessed by IC analysis, which
showed changes in EE, REE and RER (Fig 3A and 3B). We observed an increase of EE in WT
mice that underwent CR (main treatment effect, F(3,560) = 21.71, p< .0001; WT CR vs WT ST,
p< .001 Tukey HSD), and a further increase of EE in Ambra1 mice as compared to WT groups
(Ambra1 ST vs WT CR p< .001 and Ambra1 CR vs WT CR p< .001, Tukey HSD; Fig 3B).
The same pattern of increase in Ambra1 mice was observed by considering only the volume of
O2 consumed (ml/h) (S3 Fig). REE decreased in WT mice that underwent CR (main treatment
effect, F(3,472) = 151.3, p< .0001; WT CR vs WT ST, p< .0001 Tukey HSD), while the increase
of EE observed in Ambra1 mice was also present in resting condition (Ambra1 ST and
Ambra1 CR vs WT p< .0001, Tukey HSD; Fig 3B). RER was reduced in WT mice that under-
went CR as well as in Ambra1 CR mice (main treatment effect, F(3,560) = 583.3, p< .0001; WT
CR vs WT ST and Ambra1 CR vs Ambra1 ST, p< .0001 Tukey HSD). While in comparison to
WT ST mice RER was increased in Ambra1 ST mice (Ambra1 ST vs WT ST, p< .001 Tukey
HSD), Ambra1 mice that underwent CR showed a decrease of RER, indicative of a significant
shift towards a prevalent fat oxidation (Ambra1 CR vs Ambra1 ST, p< .0001 Tukey HSD; Fig
3B). However, despite the exposure to CR produced a higher fat and proteins oxidation, the
Fig 2. Metabolic changes associated to NeP and CR promote recovery. (A) The experimental timeline is schematically represented. Mechanical allodynia
measurement before CCI (pre-CCI) shows no differences between WT and A+/- mice. Effects induced by CR or ST diet on mechanical allodynia. Repeated
measures ANOVA evidenced: a diet effect (P< 0.0001) and an interaction between factors (genotype, diet and time–days postCCI; P<0.0001). From D3 to D45
�P<0.05 or ��P<0.0001 WT CR ipsilateral (IPSI) vs WT ST IPSI hindpaw and˚ p<0.05 or˚˚P<0.0001 Ambra1 mice in CR diet (A+/- CR IPSI) vs A+/- ST IPSI.
Only WT CR mice reached the contralateral (CONTRA) hindpaw (D45). (B) Body weight (g) changes at baseline (BL) and day 7 postCCI in ST or CR conditions.
(C) Glycemia (D) triglycerides, (E) glucagon and (F) insulin plasma levels at BL and at different time points from ligature (24h, D3, D7). (U = undetectable, insulin
values decrease under detection threshold (5 μU/l);˚P<0.05˚˚P<0.001 vs WT; �P<0.05 ��P<0,001 vs ST diet; §P<0.05 §§P<0,001 vs BL).
https://doi.org/10.1371/journal.pone.0208596.g002
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Fig 3. Energy and metabolic profile of WT and Ambra1 (A) Continuous 48-h recording energy expenditure (EE) in WT (ST and CR) and A+/- (ST
and CR) mice assessed via the indirect calorimetry at D7 postCCI. Heat is expressed as Kcal emitted per hour (h)/Kg. (B) Mean of 48-h whole EE, total
resting EE (REE) and respiratory exchange ratio (RER) in postCCI phase. (˚P<0.05˚˚P<0.001 vs WT; �P<0.05 ��P<0,001 vs ST; # P<0.05 ## P<0.001
vs A+/-). The small inlets above each main panel depict EE, REE and RER before in BL conditions as in Fig 1 (panel B). (C) Whole blood amino acid
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decrease of RER was significantly lower in WT than in Ambra1 mice (WT CR vs Ambra1 CR,
p< .0001 Tukey HSD; Fig 3B).
Finally, to identify potential metabolic biomarkers of neuropathic pain development and
evaluate CR-induced alteration of Ambra1 metabolic signature, we performed blood analysis
of AAs and ACCs (Fig 3C). After CCI, we observed lower levels of C10 and C18 and higher
levels of C18:1OH and Orn, in WT ST group, as compared to WT BL mice (S1 Table). By con-
trast, in the same ST condition, Ambra1 mice showed higher ACCs levels such as short-chain
ACCs (C2, C6), odd-chain ACCs (C3, C5), 3-hydroxy and dicarboxy ACCs (C4OH/C3DC,
C5DC/C6OH, C6DC, C14OH, C16OH, C18OH), and medium and long-chain ACCs (C8,
C10:1, C18:2), as well as higher levels of branched-chain AAs (BCAAs) (Val, Leu/Ile/Pro-OH)
and Tyr (Fig 3C; S1 Table), as compared to Ambra1 BL mice. Lower levels of C0 and higher
levels of medium-chain ACCs (C6, C8, C10:1, C10) and histidine (His) were detected in WT
that underwent CR, when compared to WT in ST regimen (Fig 3C; S4 Table). CR reverted
some changes in ACCs, AAs and BCAAs metabolism found in Ambra1 mice. Lower levels of
long-chain ACCs (C14, C16, C18:2, C18), 3-hydroxy and dicarboxy-ACCs (C4OH/C3DC,
C6DC, C16OH, C18OH), BCAAs (Val, Leu/Ile/Pro-OH), and Tyr (Fig 3C; S4 Table) were
found in Ambra1 mice that underwent CR, as compared to Ambra1 ST mice.
Caloric restriction counteracts neuropathy by enhancing autophagy in
Schwann cells: effects on remyelination
As previously demonstrated [13], SCs autophagy played a fundamental role in prevention of
pain chronification, and enhancement of autophagic flux had a beneficial effect in the recovery
from peripheral neuropathy.
To validate CR-induced autophagy, we analyze different autophagy markers by both immuno-
fluorescence (IF) and Western Blotting (WB) analyses of sciatic nerves. All IF images related to
CTRL animals are reported in supporting information. We found a marked LC3 immunostaining
in sciatic nerves of animals subjected to CR as compared to ST diet, more evident in WT than in
Ambra1 mice (Fig 4A and 4B and S4 Fig). To confirm the IF analysis, we observed a significant
increase in LC3-I to LC3-II conversion (H3 = 9,46 p .023; WT CR vs WT ST t4 = 5,486 p .0054;
A+/- CR vs A+/- ST t4 = 4,158 p .014; Fig 4C) together with an increase in p-ATG13 protein and a
decrease in p62 protein levels (H3 = 9,39 p .024; WT CR vs WT ST t4 = 2,86 p .045; A+/- CR vs
A+/- ST t4 = 3,29 p .03) after CR regimen (Fig 4C), suggesting autophagy induction in both geno-
types. As metabolic sensor, AMPK is strongly influenced by nutrition status. Interestingly, in
Ambra1 naïve animals, p-AMPK is highly expressed as compared to WT naïve (t4 = 5,02 p .0074),
supporting the idea that myelin aggregates already exist in basal conditions. The status of phos-
phorylation of mTOR (p-mTOR) and AMPK (p-AMPK) showed that AMPK signaling mediates
CR-induced autophagy in sciatic nerves (Fig 4D and 4E). While an increase of p-AMPK was
observed at D7 in WT ST animals subjected to CCI (t4 = -6,531 p .0028), no significant differences
were detected in Ambra1 mice which, even showing a trend of enhancement, were at the same lev-
els of naïve animals. CR produced an early occurrence of p-AMPK at D3 in WT animals (t4 = 5,19
p .006; Fig 4E) but not in Ambra1 mice, in which the sustained level of p-AMPK as observed in
naïve animals, corroborated the existence of elevated basal level of AMPK phosphorylation.
To assess myelin changes and its distribution before (naïve) and after injury (D7) we moni-
tored co-staining of glial fibrillary acidic protein (GFAP) with myelin protein zero (MPZ), and
(AA) and acylcarnitine (ACC) profiling of WT BL and A+/- BL mice vs WT and Ambra1 mice 7 days after CCI in ST dietary regimen (WT ST and A+/-
ST), and of WT ST and A+/- ST mice vs WT and Ambra1 mice under CR (WT CR and A+/- CR). � P<0.05, �� P<0.001.
https://doi.org/10.1371/journal.pone.0208596.g003
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the peripheral myelin protein of 22 kDa (PMP22), which plays a role in the maintenance of
myelin integrity (control images are reported in S5 Fig). CCI exacerbated myelin degeneration
in sciatic nerves of WT and Ambra1 mice in ST conditions (Fig 5A–5D). In WT naïve animals,
MPZ and PMP22 were regularly distributed along and inside the fiber (S5 Fig), while in CCI
condition both proteins were found aggregated and accumulated inside sciatic nerves (as
shown in Fig 5A and 5C and S5 Fig) and, as detected by enhancement of fluorescence, with
respect to control nerves (Fig 5E), mirroring the progression of Wallerian degeneration 7 days
after lesion. To the other hand, Ambra1 ST mice revealed a reduction in MPZ and PMP22
expression in comparison to WT ST (MPZ: H5 = 19,73 p .0014; PMP22: H5 = 15,96 p .0069;
Fig 5F), which is ascribable to the degenerative status (Fig 5A–5D), as later confirmed by WB
proteins analysis (Fig 5E WT ST vs A+/- ST, D7) and morphological analysis (Fig 6). CR stim-
ulated myelinogenesis both in WT and Ambra1 mice, as demonstrated by the reduction of
myelin aggregates and from changes in MPZ expression (WT CR vs WT ST t11 = 2,76 p .018;
A+/- CR vs A+/- ST t6 = 2,51 p .045), while no differences in PMP22 expression (always
reduced in Ambra1 mice) were visible (Fig 5A–5D and 5E). Increased phagocytosis might
explain the reduction of myelin aggregates in Ambra1 mice (Fig 5B; A+/- CR) as also shown
by the histological samples (Fig 6). Immunofluorescent data are corroborated by WB analysis
of myelin proteins (Fig 5F and 5G), which demonstrated a time-dependent variation of MPZ
(H13 = 38,65 p .0002) and PMP22 (H13 = 38,83 p .0002) after CCI. Of note, Ambra1 naïve mice
showed a significant reduction of MPZ (t4 = -10,371 p .0005) and an overexpression of PMP22
(t4 = 4,71 p .0092) in comparison to WT naïve (Fig 5H), indicating a basal impairment in mye-
lin proteins level. A marked time-dependent decrease of MPZ (t4 = 11,33 p .0003) and PMP22
(t4 = 63,07 p< .0001) were observed after 24h after CCI in WT ST animals, while in Ambra1
ST mice this decrease was found only from D3 (t4 = -2,972 p .041); a delay that appear imput-
able to the slower autophagic flux. CR drastically changed the profile of expression of myelin
proteins. In WT CR, both MPZ and PMP22 at 24h, resulted enhanced in comparison to WT
ST (MPZ: t4 = 4,36 p< .012; PMP22: t4 = 6,15 p .0035), reaching the same level of WT ST at
D7. On the other hand, myelin proteins of Ambra1 in CR regimen were downregulated at 24h
in comparison to Ambra1 ST (PMP22: t4 = -6,83 p .0024), then strongly upregulated at D3
(MPZ: t4 = 2,67 p .05; PMP22: t4 = 12,66 p .0002) and decreased at D7 as in WT.
These data were supported by the morphological analysis of nerve after CCI (Fig 6) versus
CTRL mice. As expected, WT mice in ST condition showed an altered morphology of nerve
structure (WT CCI ST), that was almost completely regenerated in WT mice after CR condi-
tion (WT CCI CR), resembling WT CTRL mice. Although the cross section of sciatic nerve of
CTRL WT and Ambra1 mice did not present any apparent difference (WT CTRL vs A+/-
CTRL), with normal myelinated fibers, the sciatic nerves of Ambra1 +/- mice after CCI
appeared markedly degenerated and characterized by the massive presence of phagocytes (A
+/- CCI ST). Although CR in Ambra1 mice did not induce evident sign of regeneration, except
for rare myelinated profiles (A+/- CCI CR), we observed several phagocytes and some SCs in
autophagic state, suggesting that an active phase of WD was still occurring.
Fig 4. Autophagy evaluation in Schwann cells. Representative pictures of LC3 (red) expression in SCs (GFAP–green) 7 days after CCI, in
WT (A) or in Ambra1 (B) mice both in ST and CR condition; scale bar = 60 micron. (C) Western blot (WB) analysis for autophagic
proteins (p-Atg13, p62 and LC3II) and quantification in the graph of LC3-II protein in ipsilateral ST vs ipsilateral CR nerves as ratio
between LC3-II/actin proteins (P < 0.05). (D) Sample images of SCs (GFAP–green) expressing p-mTOR (red) or p-AMPK (red) 3 days
after ligature in WT mice in ST diet or CR regimen. (E) Proteins, extracted from naïve or ipsilateral sciatic nerves from WT and A+/- mice
at 24h, 3 and 7 days from ligature in ST or RC condition, were analysed by WB using anti-pAMPK (T172), anti-AMPK, anti-p-mTOR
(S2448), anti-mTOR. Both Actin and Hsp90 were used as loading controls. Densitometric analysis of p-AMPK over Actin is also shown.
�P<0.05, ��P<0.01, ���<0.0001 vs naïve).
https://doi.org/10.1371/journal.pone.0208596.g004
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To further support remyelination of sciatic nerve, we investigated different regenerative
markers as shown in S5 Fig.
Caloric restriction activates anti-inflammatory pathways: Cytokines and
chemokines modulation
A panel of 40 pro- and anti-inflammatory mediators was used to verify the effects of CR on
cytokines and chemokines in lysates of sciatic nerves and serum at D7 post CCI (Table 1A and
1B; S5 Table). After CCI (S6A and S6B Table—WT naïve vs CCI) the following agents were
found up-regulated in nerve lysates: CCL11, GCSF, IL-1β, IL2, IL6, TIMP-1 and TNFr-I. In
the serum, the following factors were up-regulated: CD30LG, Eotaxin-1, Eotaxin-2 and GCSF
(chemokines), while others were down-regulated: IL1β, IL6, IL12p40/p70 and TNFα and its
soluble receptors (Type I and II), KC and MIP1-alpha. After exposition to CR regimen signifi-
cant changes in pro- and anti-inflammatory cytokines/chemokines expression were reported
Fig 5. Effects of CR-induced Schwann cells autophagy on remyelination. Expression of myelin protein 0 (MPZ–red) in SCs (GFAP–green), in
sciatic nerves derived from WT (A) and Ambra1 mice (B) in ST or CR condition 7 days after CCI; co-localization (merge–yellow) indicates
myelinated fibers. (C) Fibers of sciatic nerves in WT and (D) in Ambra1 mice in ST and CR regimen 7 days after CCI, double marked with S100b
(SCs—green) and the peripheral myelin protein 22 (PMP22 –red). (E) Evaluation of MPZ and PMP22 expression. MPZ is overexpressed 7 days
after CCI in WT ST vs Naïve (˚˚P<0,001) and decreased in CR vs ST (�P<0,05); in Ambra1 mice MPZ is down-expressed (§§P<0,001 vs WT ST)
and ameliorated by CR (�P<0,05 CR vs A+/- ST). PMP22 is down-expressed in Ambra1 mice in all conditions considered (§§P<0,001 A+/- vs
WT). (F) Proteins extracted from naïve or ipsilateral sciatic nerves from WT and A+/- mice at 24h, 3 and 7 days after CCI in ST or CR condition
were analysed by WB using anti-PMP22 and anti-MPZ. Actin is used as loading control. (G) Densitometric analyses of MPZ and PMPM22 over
Actin are shown. Data are expressed as the mean value±SEM (n = 3) and were analysed by two-way ANOVA followed by Bonferroni’s multiple
comparison post hoc test.˚P<0.05,˚˚P<0.001 vs naive; §P<0.05, §§P<0.001 vs WT; �P<0.05, ��P<0.001 vs ST).
https://doi.org/10.1371/journal.pone.0208596.g005
Fig 6. Effects of nerve injury and CR on myelin. Morphological changes in the distal part of sciatic nerves in semithin cross sections from WT and AMBRA1 mice,
CTRL or 7 days after CCI. Mice were analysed following ST or CR conditions (0.5 μm thick—magnification 100x; black arrows = large phagocytic cells; v = blood vessel;
A = cell in autophagic state; scale bar = 20μm).
https://doi.org/10.1371/journal.pone.0208596.g006
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(Table 1A and 1B). As far as the nerve lysates are concerned, we found a significant up-regula-
tion of the following factors: BLC, CCL24, GM-CSF, IFN-γ, TECK, TNFr-I and TNFr-II;
whereas GCSF was drastically decreased. In serum BLC, CXCL1, IL12 and MIG were up-regu-
lated, while IL1β, Eotaxin-2, Fas ligand, IL13, KC and Leptin down-regulated.
Discussion
In our previous study [13], we showed that SCs autophagy is a primary mechanism involved in
the degradation of myelin proteins after nerve injury, and that defective autophagy produced a
severe impairment in the recovery from neuropathy. Since autophagy can be mimicked by
nutrient deprivation, we used CR as autophagy inducer against NeP chronification. However,
Table 1. Cytokines modulation.
a) Nerve Lysate WT CCI D7 ST vs WT CCI D7 CR
Mediator Function Fold
change
BLC potent chemoattractant for B lymphocytes 1,98





stimulates growth of progenitors of mono, neutro-, eosino-
and basophils; activates macrophages
1,64
IFN-γ pro-inflammatory; activate macrophages 1,68
Thymus expressed chemokine (TECK) induces the migration of monocytes and other cell types
such as NK cells and dendritic cells
1,69
Soluble TNF (sTNF) receptor I endogenous inhibitors of TNF 2,07
Soluble TNF (sTNF) receptor II endogenous inhibitors of TNF 10,47
Granulocyte colony-stimulating factor
(GCSF)
stimulates growth of neutro progenitors -3,37
b) Serum WT CCI D7 ST vs WT CCI D7 CR
Mediator Function Fold
change
BLC potent chemoattractant for B lymphocytes 1,67
Fractalkine (CX3CL1) potent chemoattractant activity for T cells and monocytes;
released from apoptotic lymphocytes to stimulate
macrophage chemotaxis
1,73
IL-12 p40/p70 inflammatory cytokine inducer 1,60
Monokine induced by gamma interferon
(MIG) (CXCL9)
induces the migration of neutrophils; acts as neurotrophic
factor promoting neurite outgrowth
5,30
IL-1 beta induces IL-1,6,8,TNF, GM-CSF by macrophages;
proinflammatory
-1,58
Eotaxin-2 (CCL24) chemotactic for basophils, Th2 lymphocytes, and tryptase-
chymase mast cells
-2,64
Fas Ligand belongs to the tumor necrosis factor (TNF) family and
induces apoptosis
-2,46
Il-13 induces and mediates allergic inflammation -2,29
Keratinocyte-derived chemokine (KC)/
chemokine (C-X-C motif) ligand 1
recruits and activates leukocytes -1,54
Leptin regulates energy intake and energy expenditure -19,51
The tables show the significant decrease/increase levels of cytokines analyzed both in nerves tissue lysates samples
and in blood. Data are shown as FOLD CHANGE (CCI (ST)/NAIVE or CCI CR/CCI ST). Any� 1. 5-fold increase
or� 0. 65-fold decrease in signal intensity for a single analyte between samples may be considered a measurable and
significant difference in expression.
https://doi.org/10.1371/journal.pone.0208596.t001
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CR represents also a metabolic intervention and to understand how metabolic changes affect
the response to nerve injury and pain we analyzed different metabolic parameters both in WT
(CD1 mice) and in Ambra1 mice. We disclosed the existence of a prediabetic condition in
autophagy-defective Ambra1 mice and that nerve damage induced per se whole-body meta-
bolic changes.
Prediabetes, or borderline diabetes, is associated to a higher risk of developing diabetes.
Prediabetes occurs as an early metabolic dysregulation of glucose metabolism including
impaired fasting glucose and/or glucose intolerance with, but also without, insulin resistance
over the course of diabetic pathogenesis [32]. Investigating in fasted Ambra1 mice the meta-
bolic parameters correlated to clinical diagnosis of prediabetes, we found slight hyperglycemia,
intolerance to glucose (GTT), insulin resistance (high insulin basal levels and ITT impairment)
and hyperglucagonemia. It is worth noting that glucose homeostasis is tight regulated by the
reciprocal control exerted by insulin and glucagon circulating levels, and that hyperglucagone-
mia is recognized to account for hyperglycemia and diabetes development [33]. The predia-
betic phenotype is also supported by the identification of blood ACCs and AAs as indirect
markers of abnormal fatty acid and protein catabolism. Ambra1 mice showed higher levels of
long-chain 3-hydroxy ACCs, Orn, and Asn, and lower levels of C3 odd-chain AAs, which is a
metabolic profile predictive for the future risk of developing type 2 diabetes (T2DM), as
recently found in a population-based prospective study [34]. Notably, the best predictive abil-
ity for the increased incidence of T2DM was associated with the increase of long-chain ACCs
thus corroborating the idea of a possible dysfunction of FAO and impaired tricarboxylic acid
cycle as early dysfunctions in prodromal stage of diabetes. An association between alteration
of ACCs levels and dysfunction in glucose metabolism has been found in prediabetic subjects
[35], and the higher concentration of long-chain ACCs as marker of possible incomplete FAO
has been repeatedly confirmed in prediabetic and newly diagnosed T2DM patients [36, 37].
Together with the prediabetic phenotype, we found that energy metabolism is altered in
Ambra1 mice in which energy expenditure is enhanced in resting condition (REE) as well as
the level of oxidation of dietary fat are decreased. As for the management of body weight,
reduced fat oxidation and increased REE may be viewed as complementary factors. While the
decrease of serum triglycerides may contribute to explain the reduction of fat oxidation, it
appears that lower oxidation of dietary fat and higher REE compensate each other so that only
a slight tendency to body weight increase was observed. As reported in numerous studies [38]
increased REE accounts for an obese phenotype and/or for a predisposition to obesity, there-
fore common also in subject with prediabetes.
Hence, we hypothesized that prediabetes in Ambra1 mice may be a possible causal factor in
the exacerbation of CCI-induced neuropathy and chronic pain [13] and that by increasing
autophagy we could totally or partially relieve the neuropathic condition.
During the analysis of metabolic changes induced by CR, we first observed that peripheral
nerve injury acts as a metabolic stressor. Changes in glycemia, insulin, glucagon, triglycerides,
EE and in ACCs were found following CCI also in normometabolic mice. Nerve damage acti-
vates several metabolic processes as previously demonstrated in other neurological conditions
such as clinical and experimental traumatic spinal injuries [39]. We posit that metabolic
changes associated with nerve tissue injury facilitate chronic pain and inflammatory processes.
In this view, CR can promote faster recovery by preserving homeostasis and reducing CCI-
induced metabolic changes.
In fact, the exposure to CR not only drastically improved response to pain but also changed
the prediabetic profile of autophagy-defective mice and CCI-induced metabolic alterations.
CR induced an early recovery from allodynia in WT mice (i.e., the ipsilateral allodynic
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threshold reached the contralateral value at D45) and a decrease of allodynic response in
Ambra1 mice that approximate at D45 the spontaneous recovery observed in WT animals.
Nerve injury induced an increase of EE in Ambra1 mice in ST conditions and in both WT
and Ambra1 mice that underwent CR. Moreover, while WT CR mice showed decreased EE in
resting condition (REE), the metabolic rate was always increased in autophagy-defective mice,
irrespective of dietary regimen and motor activity. Oxidation of dietary fat, already reduced in
Ambra1 mice before the CCI, was further reduced after nerve injury. By contrast, CR induced
an increase of lipid substrate oxidation in both genotypes, which was less marked in Ambra1
animals. In Ambra1 mice, neuropathy induced an increase of different ACCs such as short-
chain, odd-chain, 3-hydroxy and dicarboxy and medium and long-chain ACCs, as well as an
increase of aromatic AA Tyr, BCAAs and direct products of BCAA catabolism. Previous stud-
ies have revealed increased levels of ACCs in T2DM and insulin resistance, supporting the
idea of an incomplete FAO as a metabolic footprint of diabetes [36, 37]. Indeed, elevation in
aromatic AAs, BCAAs and related metabolites have been described as a “metabolic signature”
for insulin resistance, glucose intolerance and obesity [36, 40].
CR improved the metabolic dysregulation found in neuropathic Ambra1 mice. Selective
long-chain acylcarnitines, some 3-hydroxy and dicarboxy-acylcarnitines, and BCAAs and Tyr
were found reduced in Ambra1 mice subjected to CR. There is evidence for a pathogenetic
link between increased BCAAs plasma levels [40, 41], persistent activation of mTOR, ribo-
somal protein S6 kinase 1 and higher risk of developing insulin resistance and T2DM. For
instance, it is recognized that leucine can stimulate the release of glucagon and insulin secre-
tion [42], and that leucine-enriched diet mediates the overstimulation of mTOR signaling and,
in turn, S6K1-mediated insulin resistance [43–45].
Since CR is a well-known autophagy inducer, we decided to evaluate its effect on neuropa-
thy, stimulation of myelin debris clearance and remyelination processes. CR strongly activates
early autophagy in WT and Ambra1 mice, as supported by the marked LC3 immunostaining
in CCI-sciatic nerves, as well as by the increase in LC3-I to LC3-II conversion. However, while
in WT animals this increase occurred via mTOR inhibition and p-AMPK, the slight improve-
ment in myelin clearance observed in Ambra1 mice appeared attributable to CR-induced mac-
rophages activity (A+/- CR, Fig 5B and 5E). CR-induced autophagy has beneficial effects on
the trophic function of SCs, and we showed that the increase of proteins associated with axon
re-growth and SCs proliferation is part of the recovery process, as for the early autophagy of
myelin debris to repair lesioned axons and production of new myelin, confirming myelino-
phagy as a major mechanism for SCs-mediated myelin clearance after nerve lesion [4] and
demonstrating the ability of SCs to respond to metabolic signals.
Since CR improved both neuropathy-associated inflammatory micro-environment and
metabolic profile, we analyzed cytokines and chemokines in response to CR regimen. As
chronic pain biomarker [46, 47], TIMP-1 resulted up-regulated by CCI and normalized by
the exposure to CR. There is also evidence for an anti-inflammatory role for AMPK [48, 49]
and several molecules involved in the stimulation and regulation of IFN-γ such as IL-12,
MIG, TNF-α receptors (I-II) were found upregulated in serum and lysates from animals sub-
jected to CR. IFN-γ participates in mTORC1 downregulation [50], and its increase corrobo-
rates the activation of autophagy machinery and macrophage activity. In the CNS, TNF-α
may have either neurotoxic or neuroprotective potential, and this dual role is believed associ-
ated with the activation of pro- or anti-apoptotic transduction pathways by the different
TNF-α receptor subtypes [51, 52]. We believe that CR may reduce TNF-α pro-inflammatory
activity by facilitating TNF-α RII activity over that of TNF-α RI via IFN-γ-mediated regula-
tion [53].
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Conclusions
Taken together, our results show that autophagy deficiency can “host” prediabetes and that the
dysmetabolic profile of Ambra1 mice fits well with the early stage of clinical diabetes. We dem-
onstrated that these conditions of borderline diabetes and defective autophagy are the mecha-
nisms responsible for the exacerbation of allodynia previously showed in Ambra1 mice. Also,
these data provide evidence that CR-induced stimulation of autophagy machinery, can exert
an effective painkiller function against neuropathy. Moreover, AMPK-mediated autophagy,
myelinogenesis and selective anti-inflammatory mechanisms play a causative role in this pro-
cess. Finally, the ability of CR to rebalance the alterations of ACCs as possible markers of
incomplete long-chain FAO in Ambra1 mice reveals the complex relationship among autop-
hagy, dietary factors, dysfunction of lipid and glucose metabolism and diabetes.
Supporting information
S1 Fig. Sex-related differences in neuropathic pain development in WT and Ambra1 mice.
Graph shows that all animals developed neuropathic pain (IPSI vs CONTRA˚˚˚ = p<0.0001)
and no differences were found in allodynic response between male (M) and female (F)
Ambra1 (A+/-) mice. A+/- F were significantly different from WT F (� = p<0.05 and ��� =
p<0.0001). Our previous data (Vacca et al. 2014, 2016) already demonstrated the different
response to nerve damage between WT male and female, as here confirmed.
(TIF)
S2 Fig. PLS-DA score plot based on whole blood amino acid (AA) and acylcarnitine (ACC)
concentrations found at baseline in wild type versus Ambra1 mice (WT BL vs A+/- BL).
(TIF)
S3 Fig. Data on the volume of O2 consumption (VO2). An increase of VO2 (ml/h) was
observed in WT CR, Ambra1 ST and Ambra1 CR but not in WT ST animals. (˚P<0.05˚˚-
P<0.001 vs WT; �P<0.05 ��P<0,001 vs ST diet; §P<0.05 §§P<0,001 vs A+/-).
(TIF)
S4 Fig. Effects of CR on Schwann cells autophagy. Autophagy is evaluated by means of LC3
staining (RED). LC3 is normally expressed in Schwann cell (GFAP–green) in basal condition
(CTRL). 7 days after CCI (CCI ST) or after the period of CR, dots of LC3 are evident, and indi-
cate that cells undergoing autophagic. The evaluation of LC3 expression (brightness values)
demonstrates the effect of treatment (H5 = 17,871 p 0.0031), an increase of autophagy after
CCI and CR in WT mice (˚˚p<0.001 and˚˚˚p<0.0001 vs CTRL), an impairment of Ambra1
mice (A+/-) in Schwann cell autophagy with respect to WT (§p<0.05 and §§ p<0.001 vs WT)
and the improvement after CR (˚p<0.05 vs CTRL).
(TIF)
S5 Fig. CCI-induced myelin degeneration and CR-increased remyelination. Sample images
(magnification 63X) of myelin markers (A) GFAP/MPZ and (B) S100b/PMP22 merge and rel-
ative zoom (2X), allowing to appreciate morphological and structural changes that occurs after
CCI and in response to CR.
(TIF)
S6 Fig. Effect of CR on sciatic nerve regenerative and structural proteins. Regenerative pro-
cesses in SCs were evaluated via the staining of different markers: cell division cycle protein 2
(CDC2), a mitotic cyclin; neurofilament 200 (NF200), a cytoskeletal protein of myelinated axons
and growth associated protein 43 (GAP43), an axonal membrane protein. Representative confocal
IF images of SCs (GFAP–green) in proliferative state (CDC2 –red) in WT (A) and Ambra1 (C)
Caloric restriction as autophagy inducer to counteract neuropathy and pain
PLOS ONE | https://doi.org/10.1371/journal.pone.0208596 December 10, 2018 21 / 26
mice sciatic nerves 7 days after CCI. After 7 days from CCI, CDC2, GAP43 and NF200 proteins
are highly expressed in damaged nerves in comparison to CTRL animals (confocal images not
shown) (B) Bar graph shows significant enhancement of CDC2 expression after CCI in WT ST vs
control (CTRL) animals (˚P<0,05) and in WT ST vs CR mice (�P<0,05). In Ambra1 mice, CR reg-
imen induced a significant enhancement vs ST and CTRL animals (P<0,05). Sample pictures of
CCI sciatic nerves double marked for intermediate neurofilaments (NF200 –green) and axonal
growth protein (GAP43 –red) in WT (D) and Ambra1 mice (F). (E) Graph shows a significant ex-
pression of GAP43 after CCI (CTRL vs WT ST;˚P<0,05) strongly enhanced by CR (��P<0,0001).
In Ambra1 mice, GAP43 expression was increased in ST condition vs CTRL (˚P<0,05). (G)
NF200 expression was significant enhanced 7 days after ligature (CTRL vs WT ST;˚˚P<0,0001).
Ambra1 mice showed any modifications in NF200 expression in all conditions considered.
(TIF)
S1 Table. Experimental groups, conditions and group size.
(PDF)
S2 Table. Whole blood amino acid and acylcarnitine profiling of wild type (WT, n = 12)
and Ambra1 (A+/-, n = 12) at baseline and 7 days after CCI in ST dietary regimen. Data are
mean concentrations expressed in μmol L-1 and p-values statistically significant (95% confi-
dence level) from two-factor mixed design ANOVA and post-hoc multiple comparisons. SD:
standard deviation. NS: not significant.
(PDF)
S3 Table. Electrospray ionization mass spectrometry (ESI-MS) acquisition parameters
used for the analysis of whole blood amino acids (AAs) and acylcarnitines (ACCs). MS/MS
transitions for each analysed AA and ACC and the corresponding internal standard (IS,
shown in bold), the optimal cone potential (V), and collision energy (eV) are shown for each
analyte. The capillary potential was 3.5 kV.
(PDF)
S4 Table. Whole blood amino acid and acylcarnitine profiling of wild type (WT) and
Ambra1 (A+/-) 7 days after CCI upon ST (WT ST, n = 12; A+/- ST, n = 7) or CR (WT CR,
n = 11; A+/- CR, n = 11) regimen. Data are mean concentrations expressed in μmol L-1 and
p-values statistically significant (95% confidence level) from two-factor ANOVA and post-hoc
multiple comparisons. SD: standard deviation. NS: not significant.
(PDF)
S5 Table. Complete map of RayBioMouse Inflammation Antibody Array G-Series utilized
for serum and nerve lysate samples.
(TIF)
S6 Table. Tables a) and b) show only the significant decrease/increase levels of cytokines
analyzed both in nerves tissue lysates samples and in blood. Data are shown as FOLD
CHANGE (CCI (ST)/NAIVE or CCI CR/CCI ST). Any� 1. 5-fold increase or� 0. 65-fold
decrease in signal intensity for a single analyte between samples may be considered a measur-
able and significant difference in expression.
(PDF)
Acknowledgments
The authors are grateful to John M. Amatruda (Diabetes & Obesity TA, Merck, Whitehouse
Station, NJ, USA) for his helpful comments, general revision and critical suggestions. The
Caloric restriction as autophagy inducer to counteract neuropathy and pain
PLOS ONE | https://doi.org/10.1371/journal.pone.0208596 December 10, 2018 22 / 26
authors thank I. Arisi and R. Brandi (EBRI–European Brain Research Institute) for technical
assistance for the chip array scanner and V. Chiurchu`, A. Leuti and A. Totaro (IRCCS Fonda-
zione Santa Lucia) for technical support in ELISA microplates readers. The authors also
acknowledge F. Cecconi (University of Tor Vergata, Italy) for providing Ambra1 gt/+ mice
line, F. Pavone and A. Moles (National Research Council–CNR, Institute of Cell Biology and
Neurobiology), F. Cecconi (University of Tor Vergata, Italy) and A. Urbani (IRCCS S. Lucia
Foundation, University of Tor Vergata) for discussion and input.
Author Contributions
Conceptualization: Roberto Coccurello, Francesca Nazio, Claudia Rossi, Sara Marinelli.
Data curation: Roberto Coccurello, Francesca Nazio, Federica De Angelis, Valentina Vacca,
Giacomo Giacovazzo, Patrizia Procacci, Valerio Magnaghi, Domenico Ciavardelli, Sara
Marinelli.
Formal analysis: Domenico Ciavardelli, Sara Marinelli.
Funding acquisition: Francesca Nazio, Claudia Rossi, Sara Marinelli.
Investigation: Francesca Nazio, Claudia Rossi, Federica De Angelis, Valentina Vacca, Gia-
como Giacovazzo, Patrizia Procacci, Sara Marinelli.
Methodology: Roberto Coccurello, Francesca Nazio, Claudia Rossi, Federica De Angelis,
Valentina Vacca, Patrizia Procacci, Valerio Magnaghi, Domenico Ciavardelli, Sara
Marinelli.
Project administration: Sara Marinelli.
Resources: Sara Marinelli.
Supervision: Roberto Coccurello, Valerio Magnaghi, Domenico Ciavardelli, Sara Marinelli.
Validation: Sara Marinelli.
Writing – original draft: Roberto Coccurello, Sara Marinelli.
Writing – review & editing: Roberto Coccurello, Francesca Nazio, Claudia Rossi, Federica De
Angelis, Valentina Vacca, Valerio Magnaghi, Domenico Ciavardelli, Sara Marinelli.
References
1. Eldin WS, Emara M, Shoker A. Prediabetes: a must to recognise disease state. Int J Clin. 2008;
62:642–648.
2. Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes
Investig. 2017; 5:646–655.
3. Yagihashi S. Glucotoxic Mechanisms and Related Therapeutic Approaches. Int Rev Neurobiol 2016.
127:121–149. https://doi.org/10.1016/bs.irn.2016.03.006 PMID: 27133148
4. Gomez-Sanchez JA, Carty L, Iruarrizaga-Lejarreta M, Palomo-Irigoyen M, Varela-Rey M, Griffith M,
Hantke J, et al. Schwann cell autophagy, myelinophagy, initiates myelin clearance from injured nerves.
J Cell Biol 2015. 210:153–168. https://doi.org/10.1083/jcb.201503019 PMID: 26150392
5. Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy. Cell Res 2014. 24:24–41.
https://doi.org/10.1038/cr.2013.168 PMID: 24366339
6. Gonzalez CD, Lee MS, Marchetti P, Pietropaolo M, Towns R, Vaccaro MI, Watada H, Wiley JW. The
emerging role of autophagy in the pathophysiology of diabetes mellitus. Autophagy 2011. 7:2–11.
https://doi.org/10.4161/auto.7.1.13044 PMID: 20935516
7. Jung HS, Chung KW, Kim JW, Kim J, Komatsu M, Tanaka K, Nguyen YH, Kang TM, Yoon KH, Kim JW,
Jeong YT, Han MS, Lee MK, Kim KW, Shin J, Lee MS. Loss of autophagy diminishes pancreatic b-cell
mass and function with resultant hyperglycemia. Cell Metab 2008. 8:318–324. https://doi.org/10.1016/j.
cmet.2008.08.013 PMID: 18840362
Caloric restriction as autophagy inducer to counteract neuropathy and pain
PLOS ONE | https://doi.org/10.1371/journal.pone.0208596 December 10, 2018 23 / 26
8. Kaniuk NA, Kiraly M, Bates H, Vranic M, Volchuk A, Brumell JH. Ubiquitinated-protein aggregates form
in pancreatic beta-cells during diabetes-induced oxidative stress and are regulated by autophagy. Dia-
betes 2007. 56:930–939. https://doi.org/10.2337/db06-1160 PMID: 17395740
9. Quan W, Hur KY, Lim Y, Oh SH, Lee JC, Kim KH, Kim GH, Kim SW, Kim HL, Lee MK, Kim KW, Kim J,
Komatsu M, Lee MS. Autophagy deficiency in beta cells leads to compromised unfolded protein
response and progression from obesity to diabetes in mice. Diabetologia 2012. 55:392–403. https://doi.
org/10.1007/s00125-011-2350-y PMID: 22075916
10. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH,
Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science
2004. 306:457–461. https://doi.org/10.1126/science.1103160 PMID: 15486293
11. Wu J, Wu JJ, Yang LJ, Wei LX, Zou DJ. Rosiglitazone protects against palmitate-induced pancreatic
beta-cell death by activation of autophagy via 50-AMP-activated protein kinase modulation. Endocrine
2013. 44:87–98. https://doi.org/10.1007/s12020-012-9826-5 PMID: 23109223
12. Fimia GM, Stoykova A, Romagnoli A, Giunta L, Di Bartolomeo S, Nardacci R, et al. Ambra1 regulates
autophagy and development of the nervous system. Nature 2007. 447:1121–1125. https://doi.org/10.
1038/nature05925 PMID: 17589504
13. Marinelli S, Nazio F, Tinari A, Ciarlo L, D’Amelio M, Pieroni L, et al. Schwann cell autophagy counteracts
the onset and chronification of neuropathic pain. Pain 2014. 155:93–107. https://doi.org/10.1016/j.pain.
2013.09.013 PMID: 24041962
14. Dubovy´ P. Wallerian degeneration and peripheral nerve conditions for both axonal regeneration and
neuropathic pain induction. Ann Anat 2011. 193:267–275. https://doi.org/10.1016/j.aanat.2011.02.011
PMID: 21458249
15. Kidd GJ, Ohno N, Trapp BD. Biology of Schwann cells. Handb Clin Neurol 2013. 115:55–79. https://
doi.org/10.1016/B978-0-444-52902-2.00005-9 PMID: 23931775
16. Bhatheja K, Field J Schwann cells: origins and role in axonal maintenance and regeneration. Int J Bio-
chem Cell Biol 2006. 38:1995–1999. https://doi.org/10.1016/j.biocel.2006.05.007 PMID: 16807057
17. Delaney CL, Russell JW, Cheng HL, Feldman EL. Insulin-like growth factor-I and over-expression of
Bcl-xL prevent glucose-mediated apoptosis in Schwann cells. J Neuropathol Exp Neurol 2001. 60:147–
160. PMID: 11273003
18. Hao W, Tashiro S, Hasegawa T, Sato Y, Kobayashi T, Tando T, et al. Hyperglycemia promotes
Schwann cell de-differentiation and de-myelination via sorbitol accumulation and Igf1 protein down-reg-
ulation. J Biol Chem 2015. 290:17106–17115. https://doi.org/10.1074/jbc.M114.631291 PMID:
25998127
19. Madeo F, Zimmermann A, Maiuri MC, Kroemer G. Essential role for autophagy in life span extension. J
Clin Invest 2015. 125:85–93. https://doi.org/10.1172/JCI73946 PMID: 25654554
20. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like
those seen in man. Pain 1988. 33:87–107. PMID: 2837713
21. Luvisetto S, Marinelli S, Cobianchi S, Pavone F. Anti-allodynic efficacy of botulinum neurotoxin A in a
model of neuropathic pain. Neuroscience 2007. 145:1–4. https://doi.org/10.1016/j.neuroscience.2006.
12.004 PMID: 17218063
22. Coccurello R, Romano A, Giacovazzo G, Tempesta B, Fiore M, Giudetti AM, Marrocco I, Altieri F,
Moles A, Gaetani S. Increased intake of energy-dense diet and negative energy balance in a mouse
model of chronic psychosocial defeat. Eur J Nutr 2017. 56:1–14
23. Giacovazzo G, Apolloni S, Coccurello R Loss of P2X7 receptor function dampens whole body energy
expenditure and fatty acid oxidation. Purinergic Signal 2018. https://doi.org/10.1007/s11302-018-9610-
y PMID: 29754194
24. Inman CF, Rees LE, Barker E, Haverson K, Stokes CR, Bailey M. Validation of computer-assisted,
pixel-based analysis of multiple-colour immunofluorescence histology. J Immunol Methods 2001.
302:156–167.
25. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H. Acevedo Arozena A,et al. Guidelines for
the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 2016. 12:1–222.
https://doi.org/10.1080/15548627.2015.1100356 PMID: 26799652
26. Bonomini M, Di Liberato L, Del Rosso G, Stingone A, Marinangeli G, Consoli A, et al. Effect of an L-car-
nitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: a 4-month,
prospective, multicenter randomized trial. Am J Kidney Dis 2013. 62:929–938. https://doi.org/10.1053/
j.ajkd.2013.04.007 PMID: 23725973
27. Di Liberato L, Arduini A, Rossi C, Di Castelnuovo A, Posari C, Sacchetta P, Urbani A, Bonomini M. L-
Carnitine status in end-stage renal disease patients on automated peritoneal dialysis. J Nephrol 2014.
27:699–706. https://doi.org/10.1007/s40620-014-0076-x PMID: 24599831
Caloric restriction as autophagy inducer to counteract neuropathy and pain
PLOS ONE | https://doi.org/10.1371/journal.pone.0208596 December 10, 2018 24 / 26
28. Sirolli V, Rossi C, Di Castelnuovo A, Felaco P, Amoroso L, Zucchelli M, et al. Toward personalized
hemodialysis by low molecular weight amino-containing compounds: future perspective of patient meta-
bolic fingerprint. Blood Transfus 2012. 10 S78–S88. https://doi.org/10.2450/2012.012S PMID:
22890273
29. Sto¨hr R, Cavalera M, Menini S, Mavilio M, Casagrande V, Rossi C, et al. Loss of TIMP3 exacerbates
atherosclerosis in ApoE null mice. Atherosclerosis 2014. 235:438–443. https://doi.org/10.1016/j.
atherosclerosis.2014.05.946 PMID: 24943223
30. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis
and interpretation. Nucleic Acids Res 2009. 37:652–660.
31. Sto¨ckli J, Fisher-Wellman KH, Chaudhuri R, Zeng XY, Fazakerley DJ, Meoli CC, et al. Metabolomic
analysis of insulin resistance across different mouse strains and diets. J Biol Chem 2017. 292
(47):19135–19145. https://doi.org/10.1074/jbc.M117.818351 PMID: 28982973
32. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 37
(Suppl.1):S14–S80
33. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and thera-
peutic makeover. J Clin Invest 2012. 122:4–12. https://doi.org/10.1172/JCI60016 PMID: 22214853
34. Sun L, Liang L, Gao X, Zhang H, Yao P, Hu Y, et al. Early Prediction of Developing Type 2 Diabetes by
Plasma Acylcarnitines: A Population-Based Study. Diabetes Care 2016. 39:1563–1570. https://doi.org/
10.2337/dc16-0232 PMID: 27388475
35. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, et al. Plasma acylcarnitine profiles sug-
gest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2
diabetic African-American women. J Nutr 2009. 139:1073–1081. https://doi.org/10.3945/jn.108.103754
PMID: 19369366
36. Mihalik SJ1, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, DeLany JP. Increased lev-
els of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxi-
city. Obesity 2010. 18:1695–1700. https://doi.org/10.1038/oby.2009.510 PMID: 20111019
37. Zhang X, Zhang C, Chen L, Han X, Ji L. Human serum acylcarnitine profiles in different glucose toler-
ance states. Diabetes Res Clin Pract 2014. 104:376–382. https://doi.org/10.1016/j.diabres.2014.04.
013 PMID: 24837145
38. Heimburger DC, Ard JD. Handbook of Clinical Nutrition (Fourth Edition) 2006. 17:371–400.
39. Kobayakawa K, Kumamaru H, Saiwai H, Kubota K, Ohkawa Y, Kishimoto J, et al. Acute hyperglycemia
impairs functional improvement after spinal cord injury in mice and humans. Sci Transl Med 2014.
6:256ra–137.
40. Giesbertz P, Daniel H. Branched-chain amino acids as biomarkers in diabetes. Curr Opin Clin Nutr
Metab Care 2016. 19:48–54. https://doi.org/10.1097/MCO.0000000000000235 PMID: 26485337
41. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-
related metabolic signature that differentiates obese and lean humans and contributes to insulin resis-
tance. Cell Metab 2009. 9:311–326. https://doi.org/10.1016/j.cmet.2009.02.002 PMID: 19356713
42. Leclercq-Meyer V, Marchand J, Woussen-Colle MC, Giroix MH, Malaisse WJ. Multiple effects of leucine
on glucagon, insulin, and somatostatin secretion from the perfused rat pancreas. Endocrinology 1985.
116:1168–1174. https://doi.org/10.1210/endo-116-3-1168 PMID: 2857640
43. Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E, et al. Overactivation of S6 kinase
1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 2005.
54:2674–2684 PMID: 16123357
44. Um SH D, Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase
1, S6K1. Cell Metab 2006. 3:393–402. https://doi.org/10.1016/j.cmet.2006.05.003 PMID: 16753575
45. Dodd KM, Tee AR (2012) Leucine and mTORC1: a complex relationship. Am J Physiol Endocrinol
Metab 302:1329–1342.
46. Rodriguez Parkitna J, Korostynski M, Kaminska-Chowaniec D, Obara, Mika J, Przewlocka B, Przew-
locki R. Comparison of gene expression profiles in neuropathic and inflammatory pain. J Physiol Phar-
macol 2006. 57:401–414. PMID: 17033093
47. Sandhir R, Gregory E, He YY, Berman NE. Upregulation of inflammatory mediators in a model of
chronic pain after spinal cord injury. Neurochem Res 2011. 36:856–862. https://doi.org/10.1007/
s11064-011-0414-5 PMID: 21287269
48. Sag D, Carling D, Stout RD, Suttles J. Adenosine 5’-monophosphate-activated protein kinase promotes
macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 2008. 181:8633–
8641. PMID: 19050283
Caloric restriction as autophagy inducer to counteract neuropathy and pain
PLOS ONE | https://doi.org/10.1371/journal.pone.0208596 December 10, 2018 25 / 26
49. Zhao X, Zmijewski JW, Lorne E, Liu G, Park YJ, Tsuruta Y, Abraham E. Activation of AMPK attenuates
neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung
Cell Mol Physiol 2008. 295:497–504.
50. Su X, Yu Y, Zhong Y, Giannopoulou EG, Hu X, Liu H, Cross J R, Ratsch G, Rice CM, Ivashkiv LB. Inter-
feron-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation.
Nat Immunol 2015. 16:838–849. https://doi.org/10.1038/ni.3205 PMID: 26147685
51. Baud V. and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol
2001. 11:372–377. PMID: 11514191
52. MacEwan DJ. TNF ligands and receptors a matter of life and death. Br J Pharmacol 2002. 135:855–
875. https://doi.org/10.1038/sj.bjp.0704549 PMID: 11861313
53. Veroni C, Gabriele L, Canini I, Castiello L, Coccia E, Remoli ME, et al. Activation of TNF receptor 2 in
microglia promotes induction of anti-inflammatory pathways. Mol Cell Neurosci 2010. 45:234–244.
https://doi.org/10.1016/j.mcn.2010.06.014 PMID: 20600925
Caloric restriction as autophagy inducer to counteract neuropathy and pain
PLOS ONE | https://doi.org/10.1371/journal.pone.0208596 December 10, 2018 26 / 26
